共 50 条
- [21] Radiosensitizing effects of ABI-007, a novel solvent-free nanoparticle albumin-bound (NAB) paclitaxel: Preclinical studies on tumor and normal tissue modelsSTRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 65 - 66Wiedenmann, N.Valdecanas, D.Hunter, N.Farrar, D.Milas, L.Mason, K. A.
- [22] Pharmacokinetics of ABI-007, cremophor-free nanoparticle formulation of paclitaxel, in Japanese and Chinese patients with malignanciesCANCER RESEARCH, 2009, 69Furushiro, KojiTamura, TomohideMinami, HironobuMukohara, ToruFujiwara, YasuhiroYamamoto, NoboruYamada, KazuhikoYamada, YasuhideNakajima, HikaruNagai, ShunjiAndo, MasashiYonemori, KanNakano, ErikoYunokawa, MayuKouno, TsutomuShimizu, ChikakoTamura, KenjiKatsumata, NoriyukiZhongzhen, GuanYamaya, HidetoshiDesai, NeilTrieu, Vuong
- [23] Increased endothelial transcytosis of nanoparticle albumin bound paclitaxel (ABI-007) by gp60-receptors: a pathway inhibited by taxol.BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S65 - S65Desai, NTrieu, VYao, RLabao, ESoon-Shiong, P
- [24] Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxelCLINICAL CANCER RESEARCH, 2006, 12 (04) : 1317 - 1324Desai, NTrieu, VYao, ZWLouie, LCi, SYang, ATao, CLDe, TBeals, BDykes, DNoker, PYao, RLabao, EHawkins, MSoon-Shiong, P
- [25] Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel: Toxicity, Pharmacokinetics, and ActivityMOLECULAR CANCER THERAPEUTICS, 2011, 10 (07) : 1300 - 1307Fu, SiqingNaing, AungMoulder, Stacy L.Culotta, Kirk S.Madoff, David C.Ng, Chaan S.Madden, Timothy L.Falchook, Gerald S.Hong, David S.Kurzrock, Razelle
- [26] A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancerSPRINGERPLUS, 2016, 5Nanda, RitaStringer-Reasor, Erica M.Saha, PoornimaKocherginsky, MashaGibson, JeanLibao, BernadetteHoffman, Philip C.Obeid, EliasMerkel, Douglas E.Khramtsova, GalinaSkor, MaxwellKrausz, ThomasCohen, Ronald N.Ratain, Mark J.Fleming, Gini F.Conzen, Suzanne D.
- [27] Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxelCLINICAL CANCER RESEARCH, 2002, 8 (05) : 1038 - 1044Ibrahim, NKDesai, NLegha, SSoon-Shiong, PTheriault, RLRivera, EEsmaeli, BRing, SEBedikian, AHortobagyi, GNEllerhorst, JA
- [28] A phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladdeJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)Smith, D. C.Grivas, P.Daignault, S.Hafez, K.Wood, D. P.Lee, C. T.Montie, J. E.Weizer, A. Z.Montgomery, J.Hussain, M.
- [29] Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 230 - +Macarulla, TeresaPazo-Cid, RobertoGuillen-Ponce, CarmenLopez, RafaelVera, RuthReboredo, MargaritaMunoz Martin, AndresRivera, FernandoDiaz Beveridge, RobertoLa Casta, AdelaidaMartin Valades, JoseMartinez-Galan, JoaquinaAles, ImmaculadaSastre, JavierPerea, SofiaHidalgo, Manuel
- [30] Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trialCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 183 - 191Ott, Patrick A.Chang, JasonMadden, KathleenKannan, RajniMuren, CarolineEscano, CrystalCheng, XinShao, YongzhaoMendoza, SandraGandhi, AlexLiebes, LeonardPavlick, Anna C.